Open AccessGenetic Variants in Histone Modification Regions Predict Clinical Outcomes of Pemetrexed Chemotherapy in Lung Adenocarcinoma
Author(s) -
Yong Hoon Lee,
Sook Kyung,
Shin Yup Lee,
Hyunwoo Kang,
Jin Eun Choi,
Mi Jeong Hong,
Jang Hyuck Lee,
Sunwoong Lee,
Won Kee Lee,
Ji Yun Jeong,
Kyung Min Shin,
Ji Eun Park,
Sun Ha Choi,
Hyewon Seo,
Seung Soo Yoo,
Jaehee Lee,
Seung Ick,
Chang Ho Kim,
Jae Yong Park
Publication year - 2022
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000527492
Subject(s) - pemetrexed , oncology , adenocarcinoma , chemotherapy , medicine , lung cancer , single nucleotide polymorphism , hazard ratio , cancer , biology , gene , genetics , genotype , cisplatin , confidence interval
This study was conducted to investigate the association between genetic variants in histone modification regions and clinical outcomes of PEM chemotherapy in patients with lung adenocarcinoma.